



## Fiscal Impact Statement for Proposed Legislation

*Virginia State Corporation Commission*

Published: April 13, 2026

### House Bill 1214

**Version:** Enrolled

**Patron:** K. Delaney

**Title:** Health insurance; cost-sharing payments for insulin and diabetes equipment and supplies; limit.

**Summary as Passed:** Decreases the cap on the cost-sharing payment that a covered person is required to pay for a covered prescription insulin drug from \$50 to \$35 for a 30-day supply of the prescription insulin drug and provides such cap is an aggregate cap that applies in situations where the covered person is prescribed more than one insulin drug. The bill also establishes such an aggregate cap of \$35 for a 30-day supply of diabetes equipment and supplies.

**Effective Date(s):** January 1, 2027

**Amendment Necessary:**  Budget, Item  
 Technical, see *Technical Note* below  
 None

---

#### *Fiscal Summary*

---

The bill has no impact on revenue.

The bill has an indeterminate impact on expenditures.

The bill has no impact on FTEs.

---

#### *Fiscal Analysis*

---

#### **Revenue**

---

There are no assumptions for revenue for this bill.

The requirements of this bill can be satisfied within the Bureau's current revenue authority.

## **Expenditures**

---

It is assumed that the Senate amendment to HB 1214 resolves the potential defrayal issue raised by the Centers for Medicare and Medicaid Services (CMS) in its proposed 2027 Notice of Benefit and Payment Parameters. This bill does not impact expenditures at the State Corporation Commission.

## **Change in FTE**

---

There is no impact on FTEs.

## **Other Comments**

---

None.

## **Technical Note**

---

None.